What are the short-acting benzodiazepines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Short-Acting Benzodiazepines

The short-acting benzodiazepines are triazolam, temazepam, lorazepam, and oxazepam, with triazolam being the shortest-acting among FDA-approved benzodiazepines for insomnia. 1

Classification by Duration of Action

Based on clinical guidelines and pharmacokinetic properties, benzodiazepines can be categorized as follows:

Ultra-Short to Short-Acting (Half-life < 8 hours)

  • Triazolam: Shortest-acting benzodiazepine, primarily used for sleep-onset insomnia 1
  • Zaleplon (technically a non-benzodiazepine BzRA): Very short half-life (2-3 hours), useful for prolonged sleep latency with minimal residual sedation 1, 2

Short to Intermediate-Acting (Half-life 8-16 hours)

  • Temazepam: Provides 8-10 hours of effect, more likely to improve sleep maintenance 1
  • Lorazepam: Can be used for anxiety and insomnia when duration of action is appropriate 1, 3
  • Oxazepam: Short-acting with lower risk of accumulation 3, 4
  • Estazolam: Short to intermediate-acting option 1

Clinical Considerations

Key pharmacokinetic principle: Benzodiazepines with mean half-lives less than 8 hours may still have residual effects, while those with half-lives greater than 16 hours are likely to cause impaired performance the next day 5. The relationship between dose and GABA-A receptor activity is hyperbolic, not linear—meaning small dose changes at low doses produce larger pharmacological effects than equivalent changes at higher doses 6.

Important Caveats

  • Triazolam warning: Associated with rebound anxiety and is not considered a first-line hypnotic despite its short duration 1
  • Residual effects: Even short-acting agents can cause next-day impairment, particularly in elderly or debilitated patients 1, 5
  • Tolerance patterns: Tolerance develops to sedation and psychomotor impairment but not to anxiolytic effects 7

Selection Algorithm

Choose based on clinical presentation:

  • Sleep-onset difficulty only: Triazolam or zaleplon (ultra-short acting) 1, 2
  • Sleep maintenance problems: Temazepam (longer duration within short-acting category) 1
  • Episodic anxiety: Oxazepam or lorazepam 4
  • Elderly patients: Start with lowest doses; consider temazepam 7.5 mg or triazolam 0.125 mg 1

Critical safety note: All benzodiazepines carry risks of tolerance, dependence, falls, cognitive impairment, and dangerous interactions with alcohol and opioids 3, 8. Infrequent, low doses of agents with short half-lives are least problematic 3.

References

Guideline

clinical guideline for the evaluation and management of chronic insomnia in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Research

Short-term versus long-term benzodiazepine therapy.

Current medical research and opinion, 1984

Research

The use of short- and long-acting hypnotics in clinical medicine.

British journal of clinical pharmacology, 1981

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.